Journal: Cancer Science

Article Title: Cancer‐testis antigen BORIS is a novel prognostic marker for patients with esophageal cancer

doi: 10.1111/j.1349-7006.2012.02355.x

Figure Lengend Snippet: Expression of BORIS m RNA in various cancer cell lines and cancer tissues and presence of BORIS ‐specific IgG in sera from patients with various cancers

Article Snippet: The cell lines used in the study were esophageal squamous cell carcinoma cell lines, TE2, TE3, TE4, TE5, TE6, TE7, TE8, TE9, TE10, TE11, TE12, TE13, TE14, and TE15 (Tohoku University, Sendai, Japan); melanoma cell lines, SKmel23, SKmel28, 888mel, A375mel, 1363mel, 928mel, 624mel, 501Amel, 586mel, 526mel, 501mel, 397mel, and 1362mel (Surgery Branch, NCI, NIH, Bethesda, MD, USA); colon cancer cell line, COLO205 (JCRB, Osaka, Japan); breast cancer cell line HS578 (American Type Culture Collection (ATCC), Manassas, VA, USA); stomach cancer cell lines, MKN1, MKN7, MKN28, MKN46, and MKN74 (Yamagata University, Yamagata, Japan); endometrial cancer cell line SNGII (Keio University, Tokyo, Japan); prostate cancer cell line LNCaP (ATCC); bladder cancer cell line, KU7 (Keio University); and brain tumor cell line U87MG (ATCC).

Techniques: Expressing

Journal: International Journal of Molecular Sciences

Article Title: BMP9 Promotes the Proliferation and Migration of Bladder Cancer Cells through Up-Regulating lncRNA UCA1

doi: 10.3390/ijms19041116

Figure Lengend Snippet: The validation of recombinant adenovirus BMP9 and siBMP9. ( A ) The expression of BMP9 in normal bladder mucosa ( n = 126), superficial bladder cancer ( n = 68), and infiltrating bladder cancer ( n = 62) in the Lee Bladder database. p = 0.007; ( B ) The expression levels of BMP9 in T24 and BIU-87 cells were detected by western blot; ( C ) The BMP9 was up-regulated in BIU-87 cells after being transfected with AdBMP9 compared to the control group; ( D ) The BMP9 was down-regulated in T24 cells after being transfected with AdsiBMP9 compared to the control group. Data are shown as mean ± SD. ** p < 0.01.

Article Snippet: Human bladder cancer BIU-87 and T24 cells were obtained from the China Center for Type Culture Collection (CCTCC).

Techniques: Biomarker Discovery, Recombinant, Expressing, Western Blot, Transfection, Control

Journal: International Journal of Molecular Sciences

Article Title: BMP9 Promotes the Proliferation and Migration of Bladder Cancer Cells through Up-Regulating lncRNA UCA1

doi: 10.3390/ijms19041116

Figure Lengend Snippet: BMP9 up-regulated the expression of lncRNA UCA1 in bladder cancer cells. ( A ) Five common lncRNA were screened in BIU-87 cells after transfected with AdBMP9 by RT-PCR; ( B ) The expression of lncRNA UCA1 were verified in BIU-87 cells after transfected with AdBMP9 by RT-PCR; ( C ) The expression of lncRNA UCA1 were tested in T24 cells after being transfected with AdsiBMP9 by RT-PCR; ( D ) The inhibitory effect of siUCA1 were analyzed by RT-PCR in BIU-87 cells after being co-transfected with AdBMP9 and siUCA1. Data are shown as mean ± SD. ns p > 0.05, * p < 0.05, ** p < 0.01, *** p < 0.001, vs. control groups.

Article Snippet: Human bladder cancer BIU-87 and T24 cells were obtained from the China Center for Type Culture Collection (CCTCC).

Techniques: Expressing, Transfection, Reverse Transcription Polymerase Chain Reaction, Control

Journal: Oncology Letters

Article Title: Cisplatin resistance by induction of aldo-keto reductase family 1 member C2 in human bladder cancer cells

doi: 10.3892/ol.2013.1768

Figure Lengend Snippet: AKR1C2 protein expression in HT1376-CisR cells was markedly increased in comparison with the parental cells. AKR1C2 small interfering RNA reduced expression by ~80% in HT1376-CisR cells. AKR1C2 and β-tubulin exhibit discrete bands of the same molecular weight (AKR1C2, 37 kDa; β-tubulin, 51 kDa). AKR1C2, aldo-keto reductase family 1 member C2; CisR, cisplatin-resistant.

Article Snippet: The human HT1376 bladder cancer cell line used in this study was purchased from DS Pharma Biomedical (Osaka, Japan).

Techniques: Expressing, Comparison, Small Interfering RNA, Molecular Weight

Journal: Oncology Letters

Article Title: Cisplatin resistance by induction of aldo-keto reductase family 1 member C2 in human bladder cancer cells

doi: 10.3892/ol.2013.1768

Figure Lengend Snippet: Effect of AKR1C2 expression on cisplatin IC 50 values in parental and HT1376-CisR cells. Cells were treated with various cisplatin concentrations for 72 h, and then quantified using a cell counter. Each assay was performed in triplicate. Cell survival in the absence of cisplatin was set as 100%. (A) Silencing AKR1C2 restored HT1376-CisR cell response to cisplatin. (B) Inhibition of AKR1C2 by 100 μM 5β-cholanic acid restored the HT1376-CisR response to cisplatin. * P<0.05, vs. HT1376-CisR. Bars indicate standard deviation. AKR1C2, aldo-keto reductase family 1 member C2; CisR, cisplatin-resistant.

Article Snippet: The human HT1376 bladder cancer cell line used in this study was purchased from DS Pharma Biomedical (Osaka, Japan).

Techniques: Expressing, Inhibition, Standard Deviation

Journal: Oncology Letters

Article Title: Cisplatin resistance by induction of aldo-keto reductase family 1 member C2 in human bladder cancer cells

doi: 10.3892/ol.2013.1768

Figure Lengend Snippet: Effect of cisplatin on intracellular ROS in HT1376 cells. Exposure to cisplatin increased the levels of intracellular ROS in HT1376 cells in a dose-dependent manner. * P<0.05, vs. HT1376 cells cultured without cisplatin. Bars indicate standard deviation. ROS, reactive oxygen species.

Article Snippet: The human HT1376 bladder cancer cell line used in this study was purchased from DS Pharma Biomedical (Osaka, Japan).

Techniques: Cell Culture, Standard Deviation

Journal: Oncology Letters

Article Title: Cisplatin resistance by induction of aldo-keto reductase family 1 member C2 in human bladder cancer cells

doi: 10.3892/ol.2013.1768

Figure Lengend Snippet: Relative values of intracellular ROS measured using a 2,7-dichlorodihydrofluorescein diacetate probe. (A) Basal intracellular ROS levels in HT1376, HT1376-CisR and HT1376-CisR cells transiently transfected with AKR1C2 small interfering RNA [HT1376-CisR-AKR1C2(−)]. * P<0.05 and $ P<0.05, vs. HT1376 and HT1376-CisR cells cultured without cisplatin, respectively. (B) Effect of 10 −4 M cisplatin exposure on intracellular ROS in these cells. (C) Effect of 5 μM menadione on intracellular ROS in these cells. * P<0.05 vs. control cells cultured without cisplatin or menadione. Bars indicate standard deviation. AKR1C2, aldo-keto reductase family 1 member C2; CisR, cisplatin-resistant; ROS, reactive oxygen species.

Article Snippet: The human HT1376 bladder cancer cell line used in this study was purchased from DS Pharma Biomedical (Osaka, Japan).

Techniques: Transfection, Small Interfering RNA, Cell Culture, Control, Standard Deviation